Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.
Pharmacyclics, Celgene Corp., Bristol-Myers Squibb, and Pfizer could see sales of new drugs eclipse $1 billion this year.
Motley Fool experts highlight three blockbuster-selling therapies that could fall by the wayside in the next five years.
Bristol-Myers Squibb this week held a conference call to discuss its fourth-quarter and full-year results. Here are five things management wants investors to know.
Bristol-Myers Squibb Co. reported its fourth quarter earnings Tuesday morning. Here's what investors need to know.
Bristol-Myers Squibb announced that its closely-watched cancer drug, Opdivo, achieved a significant clinical milestone. Here's what you need to know.
The most common reason people visit their doctor, according to a study from the Mayo Clinic, may surprise you.
The FDA approves Bristol-Myers Squibb's Opdivo, pitting it against Merck's Keytruda that was approved earlier this year.
Pfizer is a staple in most retirement and income portfolios, but investors can find stronger growth prospects in each of these three big pharmaceutical stocks.
A recent study shows that while Obamacare has dramatically reduced the number of uninsured, it's failing to provide a boost in this important area which is vital to Obamacare's long-term success.